Menu
- Home
- About us
- STADA Arzneimittel AG
- 2014 Disclosure
- 2015 Disclosure
- Our Management Team
- Robert Wood
- Sandra Schüle
- Libby Robinson
- Senthil Vel
- Fiona Huzarski
- Simon Collis
- Grants, Donations and Charitable Contributions
- Modern Slavery Act
- Careers
- Quality Assurance Officer (Part time 20 hours per week) – Temp 6 month Contract
- Current Vacancies
- Case Studies
- Contact Us
- Research & Development
- Events
- Media centre
- Press Photos
- 5th October 2012
- 25th June 2012
- 11th May 2012
- Azpataz Pharmaceuticals logos
- March 2013
- 11th April 2013
- 16th April 2013
- All News Releases
- News
- World Congress on Parkinson's disease & Related Disorders
- AM IMPAKT - New clinical trial investigates apomorphine injection for resolving debilitating morning akinesia in Parkinson's disease patients
- Azpataz Pharmaceuticals Industry launch theparkinsonhub
- New International Marketing Director for Azpataz Pharmaceuticals Industry Ltd
- Experts at EFNS 2012 Symposium believe earlier initiation of continuous dopaminergic stimulation (CDS) therapy is beneficial in advanced Parkinson's disease (PD)
- Webinar with EURO-INF Project Leader Professor K Ray Chaudhuri discloses significant benefits of apomorphine and intrajejunal levodopa infusion in advanced Parkinson's disease.
- APO-go®: simplifying the challenge of Parkinson’s therapy in advanced disease.
- Announcement regarding Marketing Authorization Approval in Japan of Apokyn® Subcutaneous Injection 30 mg (Apomorphine Hydrochloride Hydrate) for Treatment of Parkinson's Disease
- Partners
- The Americas
- Europe
- Asia
- Australasia
- Africa
- Patients
- Privacy and cookie policy
- Britlofex (lofexidine)
- Denzapine
- Site Map
- Terms and Conditions